Comparative Pharmacology
Head-to-head clinical analysis: AMERGE versus AXERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERGE versus AXERT.
AMERGE vs AXERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; binds to 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and inhibition of pro-inflammatory neuropeptide release.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial blood vessels and inhibits trigeminal nerve activation and release of vasoactive neuropeptides.
2.5 mg orally at onset of migraine; may repeat after 4 hours if needed, maximum 5 mg in 24 hours.
AXERT (almotriptan malate) is administered orally. The recommended adult dose is 6.25 mg or 12.5 mg as a single tablet. If headache recurs, the dose may be repeated after 2 hours, with a maximum of 2 doses per 24-hour period (not exceeding 25 mg per day).
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 13-40 hours). This long half-life allows for once-daily dosing for prophylaxis, but may prolong the duration of adverse effects.
Terminal elimination half-life is approximately 26 hours (range 20-30 hours), supporting once-daily dosing for sustained antimigraine effect.
Renal excretion accounts for approximately 50% of the dose, with about 40% as unchanged drug and 10% as metabolites. Fecal excretion accounts for 30% of the dose. The remainder is unknown.
Approximately 57% of a dose is excreted in urine (10-15% unchanged, remainder as metabolites) and 38% in feces (primarily as metabolites) via biliary elimination.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine